{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:51:52Z","timestamp":1792788712687,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"13th Five-Year National Science and Technology Major Project for New Drugs of\u2002the\u2002Ministry\u2002of\u2002Science\u2002and\u2002Technology\u2002of\u2002China","award":["2019ZX09734001-002-004"],"award-info":[{"award-number":["2019ZX09734001-002-004"]}]},{"name":"the Chinese National Key Technology R&D Program, Ministry of Science and Technology","award":["2017YFC0907604"],"award-info":[{"award-number":["2017YFC0907604"]}]},{"name":"Medical and health science and technology innovation project of Chinese Academy of Medical Sciences","award":["2019-I2M-2-008"],"award-info":[{"award-number":["2019-I2M-2-008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This study aims to evaluate the efficacy and safety of the iguratimod (IGU) as monotherapy or combined therapy in patients with rheumatoid arthritis (RA) by using meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched Medline, EMBASE, Cochrane library, CNKI, Wanfang medical network from initial to 30 June, 2020, for randomized clinical trials (RCTs). Two authors independently screened the studies via reading the title, abstract, and full text. The risk of bias in individual studies was assessed using the Cochrane Risk of Bias tool. STATA 12.0 was used for pooled analysis of all included studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 23 RCTs were included in this analysis. Meta-analysis showed that patients in the IGU monotherapy or combined therapy group had significantly higher ACR20 (OR = 1.97, 95% CI 1.29 to 3.00,<jats:italic>P<\/jats:italic>= 0.002), lower DAS28-CRP (SMD = \u22123.49, 95% CI \u22125.40 to \u22121.58,<jats:italic>P<\/jats:italic>&lt; 0.001) and DAS28-ESR (SMD = \u22122.61, 95% CI \u22123.64 to \u22121.57,<jats:italic>P<\/jats:italic>&lt; 0.001), as well as shorter duration of morning stiffness (SMD = \u22122.06, 95% CI \u22122.86 to \u22121.25,<jats:italic>P<\/jats:italic>&lt; 0.001) and lower HAQ score (SMD = \u22120.91, 95% CI \u22121.61 to \u22120.21,<jats:italic>P<\/jats:italic>= 0.011), than those received other disease-modifying antirheumatic drugs (DMARDs) monotherapy (primarily comprising methotrexate). For the safety profile, IGU monotherapy had similar risks for gastrointestinal reactions (<jats:italic>P<\/jats:italic>= 0.070), leucopenia (<jats:italic>P<\/jats:italic>= 0.309), increment in transaminase (<jats:italic>P<\/jats:italic>= 0.321), increase of ALT (<jats:italic>P<\/jats:italic>= 0.051), and liver damage (<jats:italic>P<\/jats:italic>= 0.182) to methotrexate monotherapy, and IGU combined with other DMARDs therapy did not increase the risks of these AEs (<jats:italic>P<\/jats:italic>&gt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our evidence suggests that IGU is effective and tolerant as monotherapy or combined therapy especially with methotrexate in patients with active RA. IGU may be regarded as a potential alternative to methotrexate, and a preferable choice when combined with other DMARDs for the treatment of RA.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13018-021-02603-2","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T05:02:55Z","timestamp":1626411775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs"],"prefix":"10.1186","volume":"16","author":[{"given":"Chao-Jun","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiu-Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"2603_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023\u201338.","journal-title":"Lancet."},{"key":"2603_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.semarthrit.2019.02.004","volume":"49","author":"M Becede","year":"2019","unstructured":"Becede M, Alasti F, Gessl I, Haupt L, Kerschbaumer A, Landesmann U, et al. Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum. 2019;49:211\u20137.","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 3","key":"2603_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/1756-185X.12539","volume":"17","author":"YM Chiu","year":"2014","unstructured":"Chiu YM, Lang HC, Lin HY, Yang MT, Fang CH, Yang YW, et al. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. Int J Rheum Dis. 2014;17(Suppl 3):9\u201319.","journal-title":"Int J Rheum Dis"},{"key":"2603_CR4","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/1744666X.2020.1686976","volume":"15","author":"G Cavalli","year":"2019","unstructured":"Cavalli G, Favalli EG. Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15:1313\u201322.","journal-title":"Expert Rev Clin Immunol"},{"key":"2603_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685\u201399.","journal-title":"Ann Rheum Dis"},{"key":"2603_CR6","unstructured":"Yuefeng C, Jianda M, Qianhua L, Lie D. The influence of biologics adherence on treating rheumatoid arthritis to target. J New Med. 2019;5:313\u20138."},{"key":"2603_CR7","doi-asserted-by":"crossref","first-page":"356040","DOI":"10.1155\/2015\/356040","volume":"2015","author":"Y Xu","year":"2015","unstructured":"Xu Y, Zhu Q, Song J, Liu H, Miao Y, Yang F, et al. Regulatory effect of iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis. Mediat Inflamm. 2015;2015:356040.","journal-title":"Mediat Inflamm"},{"key":"2603_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/PL00000291","volume":"51","author":"Y Aikawa","year":"2002","unstructured":"Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res. 2002;51:188\u201394.","journal-title":"Inflamm Res"},{"key":"2603_CR9","doi-asserted-by":"publisher","first-page":"R136","DOI":"10.1186\/ar2554","volume":"10","author":"F Du","year":"2008","unstructured":"Du F, Lu LJ, Fu Q, Dai M, Teng JL, Fan W, et al. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res Ther. 2008;10:R136.","journal-title":"Arthritis Res Ther"},{"key":"2603_CR10","first-page":"401","volume":"41","author":"Y Jiang","year":"2006","unstructured":"Jiang Y, Lu W, Yu SQ, Yao L, Xu GL, Zhang XR. Inhibitory effect of iguratimod on TNFalpha production and NF-kappaB activity in LPS-stimulated rat alveolar macrophage cell line. Yao Xue Xue Bao. 2006;41:401\u20135.","journal-title":"Yao Xue Xue Bao"},{"key":"2603_CR11","first-page":"649","volume":"15","author":"K Tanaka","year":"1992","unstructured":"Tanaka K, Aikawa Y, Kawasaki H, Asaoka K, Inaba T, Yoshida C. Pharmacological studies on 3-formylamino - 7- methylsulfonylamino - 6 -phenoxy - 4H - 1 - benzopyran - 4 - one (T-614), a novel antiinflammatory agent. 4th communication: inhibitory effect on the production of interleukin-1 and interleukin-6. Aust J Pharm. 1992;15:649\u201355.","journal-title":"Aust J Pharm"},{"key":"2603_CR12","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.4049\/jimmunol.1300832","volume":"191","author":"Q Luo","year":"2013","unstructured":"Luo Q, Sun Y, Liu W, Qian C, Jin B, Tao F, et al. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol. 2013;191:4969\u201378.","journal-title":"J Immunol"},{"key":"2603_CR13","doi-asserted-by":"crossref","unstructured":"Kong R, Gao J, Ji L, Peng Y, Zhang J, Zhao D. Iguratimod ameliorates rheumatoid arthritis progression through regulating miR-146a mediated IRAK1 expression and TRAF6\/JNK1 pathway: an in vivo and in vitro study. Clin Exp Rheumatol. 2020;39(2):289\u2013303.","DOI":"10.55563\/clinexprheumatol\/urhbn0"},{"key":"2603_CR14","first-page":"4901591","volume":"2018","author":"J Song","year":"2018","unstructured":"Song J, Liu H, Zhu Q, Miao Y, Wang F, Yang F, et al. T-614 promotes osteoblastic cell differentiation by increasing Dlx5 expression and regulating the activation of p38 and NF-kappaB. Biomed Res Int. 2018;2018:4901591.","journal-title":"Biomed Res Int"},{"key":"2603_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.intimp.2012.03.003","volume":"13","author":"F Du","year":"2012","unstructured":"Du F, Lu LJ, Teng JL, Shen N, Ye P, Bao CD. T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro. Int Immunopharmacol. 2012;13:54\u201360.","journal-title":"Int Immunopharmacol"},{"key":"2603_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.14715\/cmb\/2016.62.13.8","volume":"62","author":"XT Wang","year":"2016","unstructured":"Wang XT, Li P, Xu TS, Ding R, Zhang X, Bi LQ. Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1beta-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis. Cell Mol Biol. 2016;62:44\u201350.","journal-title":"Cell Mol Biol"},{"key":"2603_CR17","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0006-291X(02)02754-7","volume":"299","author":"K Kuriyama","year":"2002","unstructured":"Kuriyama K, Higuchi C, Tanaka K, Yoshikawa H, Itoh K. A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo. Biochem Biophys Res Commun. 2002;299:903\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"2603_CR18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/art.24643","volume":"61","author":"LJ Lu","year":"2009","unstructured":"Lu LJ, Bao CD, Dai M, Teng JL, Fan W, Du F, et al. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum. 2009;61:979\u201387.","journal-title":"Arthritis Rheum"},{"key":"2603_CR19","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s00393-015-1641-y","volume":"75","author":"Z Xia","year":"2016","unstructured":"Xia Z, Lyu J, Hou N, Song L, Li X, Liu H. Iguratimod in combination with methotrexate in active rheumatoid arthritis: therapeutic effects. Z Rheumatol. 2016;75:828\u201333.","journal-title":"Z Rheumatol"},{"key":"2603_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3109\/s10165-012-0724-8","volume":"23","author":"N Ishiguro","year":"2013","unstructured":"Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2013;23:430\u20139.","journal-title":"Mod Rheumatol"},{"key":"2603_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/1756-185X.12754","volume":"18","author":"CS Lau","year":"2015","unstructured":"Lau CS, Chia F, Harrison A, Hsieh TY, Jain R, Jung SM, et al. APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis. 2015;18:685\u2013713.","journal-title":"Int J Rheum Dis"},{"key":"2603_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/1756-185X.13513","volume":"22","author":"CS Lau","year":"2019","unstructured":"Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis. 2019;22:357\u201375.","journal-title":"Int J Rheum Dis"},{"key":"2603_CR23","first-page":"242","volume":"57","author":"Chinese Rheumatology A","year":"2018","unstructured":"Chinese Rheumatology A. 2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis. Zhonghua Nei Ke Za Zhi. 2018;57:242\u201351.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2603_CR24","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s10067-020-04986-9","volume":"39","author":"S Shrestha","year":"2020","unstructured":"Shrestha S, Zhao J, Yang C, Zhang J. Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2020;39:2139\u201350.","journal-title":"Clin Rheumatol"},{"key":"2603_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"2603_CR26","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"2603_CR27","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ."},{"key":"2603_CR28","volume-title":"Analysis of efficacy and safety of treatment of active rheumatoid arthritis with iguratimod and methotrexate","author":"L Zhao","year":"2017","unstructured":"Zhao L, Jiang Z, Zhang Y, Ma H, Cai C. Analysis of efficacy and safety of treatment of active rheumatoid arthritis with iguratimod and methotrexate; 2017."},{"key":"2603_CR29","first-page":"450","volume":"39","author":"W Zhao","year":"2016","unstructured":"Zhao W, Yao D, Huo H, Qin C, Wei Q, Sun K. Clinical study of iguratimod in the treatment of active rheumatoid arthritis. Chin J Postgrad Med. 2016;39:450\u20132.","journal-title":"Chin J Postgrad Med"},{"key":"2603_CR30","first-page":"833","volume":"32","author":"YM Xiong","year":"2015","unstructured":"Xiong YM, Fan S, Zou L. A clinical study of iguratimod combined with methotrexate on the effect of anti-cyclic citrullinated peptide antibody and other outcomes in patients with rheumatoid arthritis. J Clin Intern Med. 2015;32:833\u20135.","journal-title":"J Clin Intern Med"},{"key":"2603_CR31","first-page":"68","volume":"22","author":"H Yang","year":"2017","unstructured":"Yang H, Lin S, Yang H, Xie X, Wang X. Effect of Iguratimod on the vascular endothelial growth factor and pigment epithelial-derived factor in patients with rheumatoid arthritis. Chin J Clin Pharmacol Ther. 2017;22:68\u201371.","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"2603_CR32","first-page":"5500","volume":"38","author":"L Cao","year":"2018","unstructured":"Cao L, Yin H, Li C, Wang H, Yin S. The study of iguratimod on clinical effect and bone metabolism in patients with elderly-onset rheumatoid arthritis. Chin J Gerontol. 2018;38:5500\u20132.","journal-title":"Chin J Gerontol"},{"key":"2603_CR33","first-page":"120","volume":"19","author":"B Xu","year":"2015","unstructured":"Xu B, Mo S, Xue X. Clinical effect of methotrexate combined with iguratimod on treatment of rheumatoid arthritis. J Clin Med Pract. 2015;19:120\u20132.","journal-title":"J Clin Med Pract"},{"key":"2603_CR34","unstructured":"Hui-Ling H. Clinical effect and safety of iguratimod for treating rheumatoid arthritis. Master, Soochow University; 2014."},{"key":"2603_CR35","unstructured":"Lv J. The therapeutic effects of a combination of iguratimod and methotrexate on active rheumatoid arthritis. \u7855\u58eb, Shandong University; 2014."},{"key":"2603_CR36","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s10067-015-2999-6","volume":"34","author":"XW Duan","year":"2015","unstructured":"Duan XW, Zhang XL, Mao SY, Shang JJ, Shi XD. Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clin Rheumatol. 2015;34:1513\u20139.","journal-title":"Clin Rheumatol"},{"key":"2603_CR37","first-page":"4530","volume":"28","author":"REN Yanhong","year":"2017","unstructured":"Yanhong REN, Wei DO, Hua LIU, Lu LIU. Clinical observation of iguratimod combined with methotrexate in the treatment of rheumatoid arthritis. China Pharm. 2017;28:4530\u20133.","journal-title":"China Pharm"},{"key":"2603_CR38","first-page":"309","volume":"15","author":"S Wang","year":"2017","unstructured":"Wang S. Observation of the effect of iguratimod combined with MTX on rheumatoid arthritis. J Bethune Mil Med Coll. 2017;15:309\u201311.","journal-title":"J Bethune Mil Med Coll"},{"key":"2603_CR39","first-page":"118","volume":"28","author":"Q Bai","year":"2015","unstructured":"Bai Q. Clinical study of iguratimod combined with methotrexate in the treatment of active rheumatoid arthritis. Med Inf. 2015;28:118\u20139.","journal-title":"Med Inf"},{"key":"2603_CR40","first-page":"831","volume":"42","author":"QZ Li Xie","year":"2018","unstructured":"Li Xie QZ, Shi Y, Cheng X, Fang Y. Effect of iguratimod combined with MTX on the levels of IL-1, serum TNF-\u03b1 and VEGF in patients with refractory rheumatoid arthritis. Guizhou Medi J. 2018;42:831\u20132.","journal-title":"Guizhou Medi J"},{"key":"2603_CR41","first-page":"105","volume":"10","author":"Z Wang","year":"2016","unstructured":"Wang Z. Efficacy and safety analysis of combination of methotrexate and iguratimod in the treatment of refractory rheumatoid arthritis. Chinese J Mod Drug Appl. 2016;10:105\u20136.","journal-title":"Chinese J Mod Drug Appl"},{"key":"2603_CR42","first-page":"137","volume":"13","author":"PW Meng Deqian","year":"2016","unstructured":"Meng Deqian PW, Ju L, Hui LI, Fang LI, Shanshan LIU, Yongsheng LI, et al. Effect of methotrexate combined with iguratimod in the treatment of patients with refractory rheumatoid arthritis. China Med Herald. 2016;13:137\u201341.","journal-title":"China Med Herald"},{"key":"2603_CR43","first-page":"552","volume":"28","author":"J Chen","year":"2018","unstructured":"Chen J, ZD, Liu J. The effect of iguratimod combined with methotrexate on serum inflammatory factors and bone metabolism in patients with rheumatoid arthritis. Zhejiang J Integr Tradit Chin West Med. 2018;28:552\u20135.","journal-title":"Zhejiang J Integr Tradit Chin West Med"},{"key":"2603_CR44","first-page":"47","volume":"15","author":"XU Li-Ming","year":"2017","unstructured":"Li-Ming XU, YM, Yi-Fan LIU, Huan-Xia SUN, Li-Ning LIU, Yan-Jun SHI, et al. Clinical observation of limonoid combined with methotrexate in the treatment of rheumatoid arthritis. Guide China Med. 2017;15:47\u20138.","journal-title":"Guide China Med"},{"key":"2603_CR45","first-page":"73","volume":"23","author":"D Lu","year":"2019","unstructured":"Lu D, SX, Xiaoming Q, Wenting Z, Yao S, Yangjie L. Efficiency observation of iguratimod combined with leflunomide on the treatment of elderly patients with moderate and severe active rheumatoid arthritis. J Clin Med Pract. 2019;23:73\u20137.","journal-title":"J Clin Med Pract"},{"key":"2603_CR46","first-page":"141","volume":"34","author":"L Xuerong","year":"2018","unstructured":"Xuerong L, CY, Bangshuo Z, Jing C, Hui X, Sheng W, et al. The effect of Iguratimod combined with etanercept on CD4+, CD8+T cells and immunoglobulin of patients with refractory rheumatoid arthritis. Immunol J. 2018;34:141\u20135.","journal-title":"Immunol J"},{"key":"2603_CR47","unstructured":"Xiong M, Geng G. Clinical effect of methotrexate combined with iguratimod on active rheumatoid arthritis. Henan Med Res. 2020;1:93\u20135."},{"key":"2603_CR48","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/14397595.2013.843756","volume":"24","author":"M Hara","year":"2014","unstructured":"Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2014;24:410\u20138.","journal-title":"Mod Rheumatol"},{"key":"2603_CR49","unstructured":"Luo Q, Sun Y, Jin B, Zheng W, Shao F, Hang N, Shu Y, et al. Iguratimod synergizes with methotrexate to exert anti-inflammatory and bone-protective effect and block the progression of collagen-induced arthritis in mice. Biochem Pharmacol. 2014;3(3):135."},{"key":"2603_CR50","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/14397595.2018.1460230","volume":"29","author":"T Mimori","year":"2019","unstructured":"Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, et al. Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: final report of a 52-week, multicenter postmarketing surveillance study. Mod Rheumatol. 2019;29:314\u201323.","journal-title":"Mod Rheumatol"}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-021-02603-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-021-02603-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-021-02603-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T08:27:05Z","timestamp":1725438425000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-021-02603-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2603"],"URL":"https:\/\/doi.org\/10.1186\/s13018-021-02603-2","relation":{},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"assertion":[{"value":"2 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"457"}}